02146nam a2200385 i 4500001001300000003000300013005001700016007001400033008004100047040003000088042000800118043001200126050002100138074001900159086002300178088009000201110010700291245026200398264006000660300002700720336002600747337002700773338003100800500003600831500010800867500002600975500002501001504004101026533010601067650005101173650006801224655003301292776022601325776020901551on1000610105BD20171211174834.0he bmb024bbca170815s2016 dcua bb f000 0 eng c aPUCPRbengerdacGPOdMvI apcc an-us---14aKF27b.E553 2016 a1019-B-01 (MF)0 aY 4.C 73/8:114-114 aSerial no. 114-114 (United States. Congress. House. Committee on Energy and Commerce)1 aUnited States.bCongress.bHouse.bCommittee on Energy and Commerce.bSubcommittee on Health,eauthor.10aExamining implementation of the Biologics Price Competition and Innovation Act :bhearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Fourteenth Congress, second session, February 4, 2016. 1aWashington :bU.S. Government Publishing Office,c2016. aiii, 83 pages ;c24 cm atextbtxt2rdacontent amicroformbh2rdamedia amicrofichebhe2rdacarrier aShipping list no.: 2017-0048-M. aPaper version available for sale by the Superintendent of Documents, U.S. Government Publishing Office. a"Serial no. 114-114." aCRDP Program record. aIncludes bibliographical references. aMicrofiche.b[Washington, D.C.] :cU.S. Government Printing Office,d[2017]e1 microfiche : negative. 0aBiologicalsxGovernment policyzUnited States. 0aPharmaceutical biotechnologyxGovernment policyzUnited States. 7aLegislative hearings.2lcgft08iPrint version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.tExamining implementation of the Biologics Price Competition and Innovation Actw(DLC) 2017380681w(OCoLC)97102793508iOnline version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.tExamining implementation of the Biologics Price Competition and Innovation Actw(OCoLC)968792727